Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers

PD-1 plus CTLA-4 blockade is highly effective in advanced-stage, mismatch repair (MMR)-deficient (dMMR) colorectal cancers, yet not in MMR-proficient (pMMR) tumors. We postulated a higher efficacy of neoadjuvant immunotherapy in early-stage colon cancers. In the exploratory NICHE study (ClinicalTria...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature medicine Jg. 26; H. 4; S. 566 - 576
Hauptverfasser:	Chalabi, Myriam, Fanchi, Lorenzo F., Dijkstra, Krijn K., Van den Berg, José G., Aalbers, Arend G., Sikorska, Karolina, Lopez-Yurda, Marta, Grootscholten, Cecile, Beets, Geerard L., Snaebjornsson, Petur, Maas, Monique, Mertz, Marjolijn, Veninga, Vivien, Bounova, Gergana, Broeks, Annegien, Beets-Tan, Regina G., de Wijkerslooth, Thomas R., van Lent, Anja U., Marsman, Hendrik A., Nuijten, Elvira, Kok, Niels F., Kuiper, Maria, Verbeek, Wieke H., Kok, Marleen, Van Leerdam, Monique E., Schumacher, Ton N., Voest, Emile E., Haanen, John B.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	New York Nature Publishing Group US 01.04.2020 Nature Publishing Group
Schlagworte:	631/250 631/67 692/308/575 Adenocarcinoma - genetics Adenocarcinoma - pathology Adenocarcinoma - therapy Adult Aged Aged, 80 and over Antineoplastic Agents, Immunological - administration & dosage Antineoplastic Agents, Immunological - adverse effects Biomarkers Biomedical and Life Sciences Biomedicine Cancer Research CD8 antigen Celecoxib Cells, Cultured Colon Colon cancer Colonic Neoplasms - genetics Colonic Neoplasms - pathology Colonic Neoplasms - therapy Colorectal cancer Combined Modality Therapy Confidence intervals CTLA-4 protein Digestive System Surgical Procedures DNA Mismatch Repair - drug effects DNA Mismatch Repair - genetics Drug Administration Schedule Drug therapy Feasibility Studies Female Humans Immunotherapy Immunotherapy - adverse effects Immunotherapy - methods Infectious Diseases Ipilimumab Ipilimumab - administration & dosage Ipilimumab - adverse effects Lymphocytes Lymphocytes T Male Metabolic Diseases Metastases Middle Aged Mismatch repair Molecular Medicine Monoclonal antibodies Neoadjuvant Therapy - adverse effects Neoadjuvant Therapy - methods Neoplasm Staging Neurosciences Nivolumab - administration & dosage Nivolumab - adverse effects Patient outcomes Patients PD-1 protein Safety Surgery Targeted cancer therapy Treatment Failure Tumors Netherlands
ISSN:	1078-8956, 1546-170X, 1546-170X
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!